Friday 6-6-2014 Biogen Idec Inc (BIIB) $BIIB opene
Post# of 122
Posted On: 06/08/2014 9:50:45 PM
Friday 6-6-2014 Biogen Idec Inc (BIIB) $BIIB opened at 321.96 hitting the high price of 322.05 and a day low of 314.29 with a total volume of 873,200. BIIB had a previous close of 320.13 and has been seeing an average volume of 1,093,735.
Overall Average: 56% Buy
Recent stock forum discussions about BIIB http://investorshangout.com/search?q=BIIB&...mp;yt0=Go!
This Week in Biotech: A Trifecta of Disappointment Mars ASCO While Biogen Scores a Big Victory
Sean Williams, The Motley Fool - Motley Fool - Sat Jun 07, 12:05PM CDT
With the SPDR S&P Biotech Index up 25% over the trailing 12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and... (full story)
3 Spectacular Ways Samsung Could Disrupt the Health Care Industry
Leo Sun, The Motley Fool - Motley Fool - Sat Jun 07, 10:05AM CDT
When most investors think of Samsung , they inevitably think of smartphones, tablets, and TVs. Yet over the past several years, Samsung has also beefed up its presence in the health care industry through investments in medical devices,... (full story)
FDA clears Biogen Idec's hemophilia A drug
AP - Fri Jun 06, 5:25PM CDT
NEW YORK (AP) — U.S. regulators on Friday approved Biogen Idec's drug Eloctate, a hemophilia A treatment that is designed to last longer than older drugs. (full story)
FDA Approves Biogen Idec's ELOCTATE(TM), First Hemophilia A Therapy to Extend the Interval between Prophylactic Infusions, for Both Adults and Children
Business Wire - Fri Jun 06, 3:55PM CDT
--- Approval of Biogen Idec's Second Innovative Hemophilia Therapy with Prolonged Circulation This Year - (full story)
Human Metabolome Technologies, Inc., (HMT) Hires Alexander Buko Ph.D. as Vice President, Business and Product Development and Releases a New C13 Flux Analysis Service, F-SCOPE.
Business Wire - Fri Jun 06, 2:27PM CDT
Human Metabolome Technologies, Inc. (HMT), the leading developer of capillary electrophoresis mass spectrometry (CE-MS) based metabolomics, announces that Dr. Alexander Buko has joined the executive team in a newly created position as Vice President of HMT America reporting to President Tsutotmu Hoshiba. "I am excited that Alex will be joining our team," said Hoshiba. "Dr. Buko brings with him over 30 years of pharmaceutical experience with the FDA, Abbott Labs, and most recently with Biogen Idec where he held the position of Senior Director of Translational Medicine. Alex has successfully led large scale omics projects in neurology, immunology and oncology. With extensive experience in protein and metabolite based profiling, Alex will lead project management and develop HMT's biomarker based platforms." "I am very honored to join HMT and look forward to working with the research teams in both academia and pharmaceutical companies to further enrich metabolic research," said Buko. "HMT's commitment to delivering quantitative and metabolic profiling will set the standard for discovery research to come." (full story)
Jim Cramer: No Joy in Shortville
at The Street - Fri Jun 06, 12:42PM CDT
Shorts take much more homework than longs. (full story)
'Mad Money' Lightning Round: I'm Flying With American
at The Street - Fri Jun 06, 5:00AM CDT
Cramer is a believer in Charles Schwab and likes Gilead Sciences and Celgene. (full story)
Stock Market News for June 05, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Jun 05, 9:06AM CDT
Benchmarks erased day’s initial losses and ended in the green after investors shrugged off dismal labor market data to focus on an encouraging services sector report (full story)
Technical Snapshot on Biotech Stocks -- Research on Aegerion Pharma, Biogen Idec, Lexicon Pharma, and Curis
PR Newswire - Thu Jun 05, 7:30AM CDT
The US markets on Wednesday, June 4, 2014 ended on a positive note as the Dow Jones Industrial Average finished at 16,737.53, up 0.09% and the NASDAQ Composite closed at 4,251.64, up 0.41%. The S&P 500 finished the session 0.19% higher at 1,927.88. During the trading session, seven out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 694.30, up 0.23%, with the index advancing 3.81% in the last one month. Investor-Edge has initiated coverage on the following equities: Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR), Biogen Idec Inc. (NASDAQ: BIIB), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) and Curis Inc. (NASDAQ: CRIS). Free technical research on AEGR, BIIB, LXRX and CRIS can be downloaded upon signing up at: (full story)
Biotech Stock Roundup: Gilead, Pharmacyclics Impress at ASCO - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jun 04, 11:14AM CDT
It was ASCO all the way with several biotech companies presenting data at the highly-awaited annual meeting. (full story)
Indolent Lymphoma - Pipeline Review, H1 2014
M2 - Wed Jun 04, 6:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sw248r/indolent_lymphoma) has announced the addition of the "Indolent Lymphoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Indolent Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Indolent Lymphoma and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Companies Mentioned: - Accentia Biopharmaceuticals, Inc. - Astellas Pharma Inc. - Bayer AG - Biogen Idec Inc. - Celgene Corporation - Cell Therapeutics, Inc. - Emergent BioSolutions Inc. - F. Hoffmann-La Roche Ltd. - Gilead Sciences, Inc. - Incyte Corporation - Infinity Pharmaceuticals, Inc. - Merck & Co., Inc. - Merck KGaA - Pharmacyclics, Inc. - Sandoz Inc. For more information visit http://www.researchandmarkets.com/research/sw...t_lymphoma (full story)
Malignant Pleural Mesothelioma - Pipeline Review, H1 2014
M2 - Wed Jun 04, 6:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/82dd4m/malignant_pleural) has announced the addition of the "Malignant Pleural Mesothelioma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Pleural Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Pleural Mesothelioma and special features on late-stage and discontinued projects. This report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Companies Mentioned: - Boehringer Ingelheim GmbH - Biogen Idec Inc. - Merck & Co., Inc. - Oxford BioMedica plc - Novartis AG - Pfizer Inc. - Bionomics Limited - Synta Pharmaceuticals Corp. - Morphotek, Inc. - Virttu Biologics Limited - CanBas Co., Ltd. - MolMed S.p.A. - Genelux Corporation - Polaris Group - Verastem, Inc. For more information visit http://www.researchandmarkets.com/research/82...nt_pleural (full story)
Critical Alerts For Tesla, Apple, Ryder System, ExOne, and Biogen Idec Released By InvestorsObserver
PR Newswire - Tue Jun 03, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for TSLA, AAPL, R, XONE, and BIIB. (full story)
Upcoming Shareholders Meeting, Multi-Choice Medical Plans, FDA Approvals, and Investor Conference Schedules - Analyst Notes on Biogen Idec, UnitedHealth Group, Amgen, WellPoint and Mylan
PR Newswire - Tue Jun 03, 6:00AM CDT
Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), UnitedHealth Group Inc. (NYSE: UNH), Amgen, Inc. (NASDAQ: AMGN), WellPoint Inc. (NYSE: WLP) and Mylan Inc. (NASDAQ: MYL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3241-100free. (full story)
Alexandria Real Estate Equities, Inc. Receives LEED Gold Certification for Biogen Idec Inc.'s Build-to-Suit Headquarters in Cambridge, Massachusetts
PR Newswire - Mon Jun 02, 7:30AM CDT
Alexandria Real Estate Equities, Inc. (NYSE:ARE), an approximately $9 billion total market capitalization real estate investment trust (REIT) uniquely focused on clustering Class A assets in collaborative science and technology campuses in urban innovation centers, announced today that 225 Binney Street, an approximately 305,000 rentable-square-foot (RSF), world-class, build-to-suit headquarters space fully leased to Biogen Idec Inc. in Cambridge, Massachusetts, has achieved LEED® Gold Certification for Core and Shell from the US Green Building Council (USGBC). LEED, or Leadership in Energy & Environmental Design, recognizes best-in-class, innovative green building strategies, design, and construction practices. By granting this elite designation, the USGBC recognizes 225 Binney Street for its excellence in design, energy consumption, water efficiency, and environmental quality, affirming Alexandria's expertise in developing science and technology campuses at the forefront of sustainability and operational efficiency. (full story)
Anti-Depressants: The Secret to Preventing Alzheimer's?
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Sat May 31, 3:52PM CDT
The Science Translational Medicine journal recently published research about the generic antidepressant citalopram, which was developed by Forest Laboratories under the brand name Celexa, as a potential way to help slow down the development of... (full story)
Is This Really the Best Pipeline In Biotech?
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Fri May 30, 7:21PM CDT
Any disappointment from ISIS Pharmaceuticals recent earnings has been forgotten. While Kynamro may not be selling to the degree investors hoped for, a clincial trial success for a new blood thinner has shares headed higher at the end of the month.... (full story)
Apple, Facebook, Valeant Among 5 Top IBD 50 Big Caps
at Investor's Business Daily - Fri May 30, 6:55PM CDT
Apple rocked the market with its purchase of Beats Electronics on Wednesday. But the personal electronics giant's shares have been on the uptick since reporting strong quarterly sales on April 23. Apple is among the top big-cap stocks on the IBD 50.... (full story)
Overall Average: 56% Buy
Recent stock forum discussions about BIIB http://investorshangout.com/search?q=BIIB&...mp;yt0=Go!
This Week in Biotech: A Trifecta of Disappointment Mars ASCO While Biogen Scores a Big Victory
Sean Williams, The Motley Fool - Motley Fool - Sat Jun 07, 12:05PM CDT
With the SPDR S&P Biotech Index up 25% over the trailing 12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and... (full story)
3 Spectacular Ways Samsung Could Disrupt the Health Care Industry
Leo Sun, The Motley Fool - Motley Fool - Sat Jun 07, 10:05AM CDT
When most investors think of Samsung , they inevitably think of smartphones, tablets, and TVs. Yet over the past several years, Samsung has also beefed up its presence in the health care industry through investments in medical devices,... (full story)
FDA clears Biogen Idec's hemophilia A drug
AP - Fri Jun 06, 5:25PM CDT
NEW YORK (AP) — U.S. regulators on Friday approved Biogen Idec's drug Eloctate, a hemophilia A treatment that is designed to last longer than older drugs. (full story)
FDA Approves Biogen Idec's ELOCTATE(TM), First Hemophilia A Therapy to Extend the Interval between Prophylactic Infusions, for Both Adults and Children
Business Wire - Fri Jun 06, 3:55PM CDT
--- Approval of Biogen Idec's Second Innovative Hemophilia Therapy with Prolonged Circulation This Year - (full story)
Human Metabolome Technologies, Inc., (HMT) Hires Alexander Buko Ph.D. as Vice President, Business and Product Development and Releases a New C13 Flux Analysis Service, F-SCOPE.
Business Wire - Fri Jun 06, 2:27PM CDT
Human Metabolome Technologies, Inc. (HMT), the leading developer of capillary electrophoresis mass spectrometry (CE-MS) based metabolomics, announces that Dr. Alexander Buko has joined the executive team in a newly created position as Vice President of HMT America reporting to President Tsutotmu Hoshiba. "I am excited that Alex will be joining our team," said Hoshiba. "Dr. Buko brings with him over 30 years of pharmaceutical experience with the FDA, Abbott Labs, and most recently with Biogen Idec where he held the position of Senior Director of Translational Medicine. Alex has successfully led large scale omics projects in neurology, immunology and oncology. With extensive experience in protein and metabolite based profiling, Alex will lead project management and develop HMT's biomarker based platforms." "I am very honored to join HMT and look forward to working with the research teams in both academia and pharmaceutical companies to further enrich metabolic research," said Buko. "HMT's commitment to delivering quantitative and metabolic profiling will set the standard for discovery research to come." (full story)
Jim Cramer: No Joy in Shortville
at The Street - Fri Jun 06, 12:42PM CDT
Shorts take much more homework than longs. (full story)
'Mad Money' Lightning Round: I'm Flying With American
at The Street - Fri Jun 06, 5:00AM CDT
Cramer is a believer in Charles Schwab and likes Gilead Sciences and Celgene. (full story)
Stock Market News for June 05, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Jun 05, 9:06AM CDT
Benchmarks erased day’s initial losses and ended in the green after investors shrugged off dismal labor market data to focus on an encouraging services sector report (full story)
Technical Snapshot on Biotech Stocks -- Research on Aegerion Pharma, Biogen Idec, Lexicon Pharma, and Curis
PR Newswire - Thu Jun 05, 7:30AM CDT
The US markets on Wednesday, June 4, 2014 ended on a positive note as the Dow Jones Industrial Average finished at 16,737.53, up 0.09% and the NASDAQ Composite closed at 4,251.64, up 0.41%. The S&P 500 finished the session 0.19% higher at 1,927.88. During the trading session, seven out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 694.30, up 0.23%, with the index advancing 3.81% in the last one month. Investor-Edge has initiated coverage on the following equities: Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR), Biogen Idec Inc. (NASDAQ: BIIB), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) and Curis Inc. (NASDAQ: CRIS). Free technical research on AEGR, BIIB, LXRX and CRIS can be downloaded upon signing up at: (full story)
Biotech Stock Roundup: Gilead, Pharmacyclics Impress at ASCO - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jun 04, 11:14AM CDT
It was ASCO all the way with several biotech companies presenting data at the highly-awaited annual meeting. (full story)
Indolent Lymphoma - Pipeline Review, H1 2014
M2 - Wed Jun 04, 6:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sw248r/indolent_lymphoma) has announced the addition of the "Indolent Lymphoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Indolent Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Indolent Lymphoma and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Companies Mentioned: - Accentia Biopharmaceuticals, Inc. - Astellas Pharma Inc. - Bayer AG - Biogen Idec Inc. - Celgene Corporation - Cell Therapeutics, Inc. - Emergent BioSolutions Inc. - F. Hoffmann-La Roche Ltd. - Gilead Sciences, Inc. - Incyte Corporation - Infinity Pharmaceuticals, Inc. - Merck & Co., Inc. - Merck KGaA - Pharmacyclics, Inc. - Sandoz Inc. For more information visit http://www.researchandmarkets.com/research/sw...t_lymphoma (full story)
Malignant Pleural Mesothelioma - Pipeline Review, H1 2014
M2 - Wed Jun 04, 6:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/82dd4m/malignant_pleural) has announced the addition of the "Malignant Pleural Mesothelioma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Pleural Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Pleural Mesothelioma and special features on late-stage and discontinued projects. This report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Companies Mentioned: - Boehringer Ingelheim GmbH - Biogen Idec Inc. - Merck & Co., Inc. - Oxford BioMedica plc - Novartis AG - Pfizer Inc. - Bionomics Limited - Synta Pharmaceuticals Corp. - Morphotek, Inc. - Virttu Biologics Limited - CanBas Co., Ltd. - MolMed S.p.A. - Genelux Corporation - Polaris Group - Verastem, Inc. For more information visit http://www.researchandmarkets.com/research/82...nt_pleural (full story)
Critical Alerts For Tesla, Apple, Ryder System, ExOne, and Biogen Idec Released By InvestorsObserver
PR Newswire - Tue Jun 03, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for TSLA, AAPL, R, XONE, and BIIB. (full story)
Upcoming Shareholders Meeting, Multi-Choice Medical Plans, FDA Approvals, and Investor Conference Schedules - Analyst Notes on Biogen Idec, UnitedHealth Group, Amgen, WellPoint and Mylan
PR Newswire - Tue Jun 03, 6:00AM CDT
Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), UnitedHealth Group Inc. (NYSE: UNH), Amgen, Inc. (NASDAQ: AMGN), WellPoint Inc. (NYSE: WLP) and Mylan Inc. (NASDAQ: MYL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3241-100free. (full story)
Alexandria Real Estate Equities, Inc. Receives LEED Gold Certification for Biogen Idec Inc.'s Build-to-Suit Headquarters in Cambridge, Massachusetts
PR Newswire - Mon Jun 02, 7:30AM CDT
Alexandria Real Estate Equities, Inc. (NYSE:ARE), an approximately $9 billion total market capitalization real estate investment trust (REIT) uniquely focused on clustering Class A assets in collaborative science and technology campuses in urban innovation centers, announced today that 225 Binney Street, an approximately 305,000 rentable-square-foot (RSF), world-class, build-to-suit headquarters space fully leased to Biogen Idec Inc. in Cambridge, Massachusetts, has achieved LEED® Gold Certification for Core and Shell from the US Green Building Council (USGBC). LEED, or Leadership in Energy & Environmental Design, recognizes best-in-class, innovative green building strategies, design, and construction practices. By granting this elite designation, the USGBC recognizes 225 Binney Street for its excellence in design, energy consumption, water efficiency, and environmental quality, affirming Alexandria's expertise in developing science and technology campuses at the forefront of sustainability and operational efficiency. (full story)
Anti-Depressants: The Secret to Preventing Alzheimer's?
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Sat May 31, 3:52PM CDT
The Science Translational Medicine journal recently published research about the generic antidepressant citalopram, which was developed by Forest Laboratories under the brand name Celexa, as a potential way to help slow down the development of... (full story)
Is This Really the Best Pipeline In Biotech?
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Fri May 30, 7:21PM CDT
Any disappointment from ISIS Pharmaceuticals recent earnings has been forgotten. While Kynamro may not be selling to the degree investors hoped for, a clincial trial success for a new blood thinner has shares headed higher at the end of the month.... (full story)
Apple, Facebook, Valeant Among 5 Top IBD 50 Big Caps
at Investor's Business Daily - Fri May 30, 6:55PM CDT
Apple rocked the market with its purchase of Beats Electronics on Wednesday. But the personal electronics giant's shares have been on the uptick since reporting strong quarterly sales on April 23. Apple is among the top big-cap stocks on the IBD 50.... (full story)
(0)
(0)Biogen Inc. (BIIB) Stock Research Links
Scroll down for more posts ▼